Vice President, Clinical Development
iTeos Therapeutics
Dr. Angela James is Vice President, Clinical Development at iTeos Therapeutics, has been a member of ASCPT since 1995. She is currently a member of the Joint Steering Committee for the Oncology Community and the Special Programming Committee for the 2023 Annual Meeting. Prior to joining iTeos Therapeutics, Dr. James was Head of Climical Pharmacology at MacroGenics Inc. Dr. James held roles of increasing responsibility as the Global Clinical Pharmacology Lead at Astellas, Celgene and Alcon/Novartis. Prior to leaving Astellas, Dr. James transitioned to the role of Global Development Project Leader and led cross-functional project teams to successfully execute on global strategies for the development of novel immuno-oncology agents including an innovative cancer vaccine. Dr. James earned a B.A. in Biology from Rice University and a Ph.D. in Pharmaceutical Sciences with a research focus in Pharmacokinetic/Pharmacodynamic Modeling and Simulation from University of Maryland, Baltimore. She also earned a M.S. in Pharmacometrics from University of Maryland, Baltimore. Dr. James is passionate about utilizing her scientific acumen and leadership abilities to bring novel therapeutics to patients who urgently need safe and effective drugs.
Disclosure(s): Iteos Therapeutics: Employment (Ongoing); Macrogenics: Employment (Terminated), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Terminated)
Thursday, March 28, 2024
5:55 PM – 6:25 PM MDT